SCHEMBL428384

SCHEMBL428384

O=C1CCc2cc(O)cc(Cl)c2N1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.51
CYP11B2 P19099 7/20 0.51
CYP1A2 P05177 1/20 0.51
AHR P35869 1/20 0.41
CYP19A1 P11511 4/20 0.39
SRD5A1 P18405 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPC1 O15118 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
CA9 Q16790 1/20 0.36
CRBN Q96SW2 1/20 0.36
MAOB P27338 2/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9378752 0.83 CYP11B1 (0.52) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL14779528 0.80 CYP11B1 (0.50) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL7278086 0.80 CYP11B1 (0.50) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL424061 0.80 AKT1 (0.42) CYP11B1CYP11B2CYP1A2CYP19A1SRD5A1
SCHEMBL12559608 0.80 CYP11B1 (0.50) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL8553375 0.80 CYP11B1 (0.50) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL1289709 0.80 KIF11 (0.46) CYP11B1CYP11B2CYP1A2CYP19A1SRD5A1
SCHEMBL19737432 0.76 CYP11B1 (0.47) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL10570657 0.76 CYP11B1 (0.41) CYP11B1CYP11B2CYP1A2AHRCYP19A1
SCHEMBL15828561 0.76 CYP11B1 (0.47) CYP11B1CYP11B2CYP1A2AHRCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609847-B2 Dihydroquinolinone derivatives TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-12-17 US disclosed
EP-2393802-B1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-08 EP disclosed
EP-2393802-B1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-08 EP disclosed
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-26 US disclosed
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-26 US disclosed
EP-2393802-A1 DIHYDROQUINOLINONE DERIVATIVES Taisho Pharmaceutical Co., Ltd. (JP) 2011-12-14 EP disclosed
WO-2010090347-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-12 WO disclosed
WO-2010090347-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES PER2, CRY1, BACE1 CYP11B1 918/4885CYP11B2 772/4885CYP1A2 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.